Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
Authors
Keywords
-
Journal
Experimental Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-24
DOI
10.1186/s40164-023-00412-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity
- (2022) Matthew R. Strickland et al. Cancer Discovery
- Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)
- (2022) Meichen Li et al. OncoImmunology
- Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape
- (2021) Seung Geun Song et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Current approaches to the management of brain metastases
- (2020) John H. Suh et al. Nature Reviews Clinical Oncology
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2020) Shirish Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
- (2020) Sarah B Goldberg et al. LANCET ONCOLOGY
- Systemic treatment of brain metastases in non-small cell lung cancer
- (2020) Simon Page et al. EUROPEAN JOURNAL OF CANCER
- Management of brain metastases according to molecular subtypes
- (2020) Riccardo Soffietti et al. Nature Reviews Neurology
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Brain metastases
- (2019) Achal Singh Achrol et al. Nature Reviews Disease Primers
- Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer
- (2019) Sha Zhao et al. Cancer Immunology Research
- Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
- (2019) Lizza E.L. Hendriks et al. Journal of Thoracic Oncology
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer
- (2019) Y Kudo et al. ANNALS OF ONCOLOGY
- Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
- (2019) Tao Jiang et al. Journal of Hematology & Oncology
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases
- (2018) Clément Gauvain et al. LUNG CANCER
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
- (2018) Amanda Jane Williams Gibson et al. MEDICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
- (2018) Terry L. Ng et al. CANCER
- OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2017) O. Molinier et al. Journal of Thoracic Oncology
- The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
- (2016) Solange Peters et al. CANCER TREATMENT REVIEWS
- EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases
- (2016) Tao Jiang et al. Journal of Thoracic Oncology
- Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
- (2016) Elizabeth Dudnik et al. LUNG CANCER
- High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules
- (2015) Chunyan Wu et al. Journal of Thoracic Oncology
- EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer
- (2015) Yan Wang et al. Journal of Thoracic Oncology
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Metastatic sites and survival in lung cancer
- (2014) M. Riihimäki et al. LUNG CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More